Kinarus announces CHF 20 million convertible bond issue
Kinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.
Cancer: Western life style is a killer
A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.
Ryvu Therapeutics bags 22m from EIB
Polish cancer drug developer, Ryvu Therapeutics, has received 22m funding from the European Investment Bank via its venture debt instrument.
Largest beer brewer to use sustainable PEF bottles
Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
Vector Biopharma kicks of with CHF30m Series A financing
With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.
Two deaths with Novartis gene therapy
Swiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.
Azenta set to acquire B Medical Systems
Azenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for 410m.
Sartorius pays £415m for Albumedix Ltd
Sartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
BioNtech SE expands collab with Genmab A/S
As Genmabs Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.
F2G to use $70m financing to advance olorofilm
British antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.